Vancouver, BC – November 5, 2014. Augurex Life Sciences Corp. announces a burgeoning body of data that further reveals the important role of a protein measured in blood, called 14-3-3eta, in rheumatoid arthritis (RA). Ten studies will be presented at the world’s...
The National Research Council of Canada (NRC) and Augurex Life Sciences Corp. are proud to announce a collaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine. By combining their research and development expertise, NRC...
Vancouver, BC – May 29, 2014. Augurex Life Sciences Corp. announces a ground-breaking body of new data that will publish during the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology taking place June 11-14 in Paris. Investigators will present...
Vancouver, BC – October 25, 2013 – Augurex Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting,...
International arthritis investigators this week at the 2012 Annual Meeting of the American College of Rheumatology held in Washington, DC presented data related to the 14-3-3η protein and its auto-antibodies, a promising set of new blood-based markers from Augurex,...
Augurex Life Sciences Corp. today announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex’s rheumatoid arthritis (RA) 14-3-3η...
When early discoveries are made at universities, they usually require additional research and funding to uncover what the innovation’s clinical usefulness will be to patients and physicians. For example, in 2006 researchers at the University of British Columbia...
At Europe’s premier arthritis congress, the European League Against Rheumatism (EULAR) last week in Berlin, researchers presented findings that a protein measurable in blood named 14-3-3η, marks the presence of joint damage in two different forms of arthritis,...
Not unlike cancer, disease outcome can be dramatically improved if RA is caught and treated early. Augurex Life Sciences Corp. reported that in Chicago at the American College of Rheumatology (ACR) Annual Scientific Meeting, world-leading arthritis researchers from...
Company’s novel biomarker and drug target could represent the first personalized medicine in RA promise for future targeted therapy in a multi-factorial disease. Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism...
